Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology Class A Ordinary Shares
Your view on NNNN
Overview
What the company does, where it operates, and who runs it.
About Anbio Biotechnology Class A Ordinary Shares
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Michael Lau
- Headquarters
- DE
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Michael Lau
- Headquarters
- DE
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.
It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets.
The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Anbio Biotechnology Class A Ordinary Shares, and the rating behind it. NNNN last traded at $6.34, 32.7× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Anbio Biotechnology Class A Ordinary Shares. Starting points for Anbio Biotechnology Class A Ordinary Shares: P/E 32.7, EPS $0.19, beta 5.13 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Anbio Biotechnology Class A Ordinary Shares. Anbio Biotechnology Class A Ordinary Shares does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Anbio Biotechnology Class A Ordinary Shares. Trailing twelve-month EPS for Anbio Biotechnology Class A Ordinary Shares stands at $0.19. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Anbio Biotechnology Class A Ordinary Shares. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Anbio Biotechnology Class A Ordinary Shares valued side by side against its closest peers. Anbio Biotechnology Class A Ordinary Shares is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Anbio Biotechnology Class A Ordinary Shares, and how their positions are changing. At a $278.3M market value, institutional positions materially move Anbio Biotechnology Class A Ordinary Shares's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Anbio Biotechnology Class A Ordinary Shares executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Anbio Biotechnology Class A Ordinary Shares. Anbio Biotechnology Class A Ordinary Shares is a $278.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Anbio Biotechnology Class A Ordinary Shares. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Anbio Biotechnology Class A Ordinary Shares. Coverage tracks Anbio Biotechnology Class A Ordinary Shares within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.